Accurate Education: 

Visual Snow Syndrome

Treatment Protocol

No single published protocol exists for comprehensive, phased VSS treatment. The following framework synthesizes available evidence drawing from pharmacologic trials, nutraceutical data, and non-pharmacologic studies — into a structured,  four-phase approach organized by evidence strength, safety, and practical sequencing.

 

See:  

  

 

  

Key to Links:

  • Grey text – handout
  • Red text – another page on this website
  • Blue text – Journal publication

Definitions and Terms Related to Pain

 

Visual Snow Syndrome:

Treatment

Guiding Principles

Before initiating treatment, several foundational steps are essential:

  1. Screen for comorbidities. Over 50% of VSS patients have comorbid migraine (predominantly with aura), and ≥50% have active depression or anxiety. Tinnitus is present in ~52%. These conditions independently worsen disease burden and coping, and treating them may improve overall outcomes.[1]
  2. Identify and eliminate exacerbating factors. Recreational drugs and alcohol worsen VS symptoms in multiple reports. Certain antidepressants (particularly SSRIs/SNRIs) can trigger or worsen visual symptoms. Indoor and fluorescent lighting have a worse effect on symptoms compared with natural outdoor lighting.[2][3][4]
  3. Set realistic expectations. No treatment has achieved complete remission in the majority of patients. The goal is cumulative partial benefit across multiple modalities, improved functional capacity, and reduced distress — not cure.[1][5]

PHASE 1 (Weeks 0–4):

Foundation — Education, Environment, and Nutraceuticals

This phase is low-risk, immediately actionable, and establishes the therapeutic foundation before introducing pharmacotherapy.

Education and Validation

A simple, empathic discussion of the diagnosis itself is therapeutic. Ciuffreda & Rutner (2025) identify patient education as one of six therapeutic approaches, noting that understanding the benign, non-progressive nature of VSS reduces anxiety-driven symptom amplification. VSS symptoms perpetuate partly through attentional mechanisms — heightened vigilance and threat attribution — so reframing the condition early is critical.[6][7]

Environmental Modifications

  • Transition to natural or warm-spectrum lighting where possible; avoid fluorescent lights, which worsen symptoms.[2]
  • Reduce screen brightness and use blue-light filters on digital devices.
  • Avoid alcohol, recreational drugs, and cannabis — all documented to worsen VS.[2][3]
  • Review medication list: discontinue or substitute any SSRIs/SNRIs or other medications that may be exacerbating visual symptoms, if clinically feasible.[4]

Nutraceutical Initiation

  • Magnesium — Start 200 mg/day elemental (citrate, glycinate, or taurate formulation), titrate to 400–600 mg/day over 1–2 weeks as GI tolerance allows.
  • Riboflavin — 400 mg/day (or 200 mg BID for improved absorption). Counsel about harmless yellow urine discoloration.[8]
  • CoQ10 — 300 mg/day, taken with a fat-containing meal.

Rationale for starting nutraceuticals first: In the 400-patient VSS study by Puledda et al. (2022), vitamins had the highest therapeutic ratio of any treatment class — they were among the few interventions more likely to help than harm.[2] Starting these before lamotrigine also allows clear attribution of any adverse effects when pharmacotherapy is later introduced.

FL-41 or Chromatic Tinted Lenses

  • Prescribe FL-41 tinted lenses as an immediate, low-risk intervention. FL-41 consistently provides symptom relief across multiple VSS reviews.[9]
  • If available, refer for Intuitive Colorimeter assessment by a neuro-optometrist for individualized tint selection (80% of patients were prescribed a tint with mean 45% VS reduction in the Han et al. retrospective series).[10]

PHASE 2 (Weeks 4–16):

Pharmacotherapy — Lamotrigine Titration

After 4 weeks on the nutraceutical foundation, introduce lamotrigine with standard slow titration to minimize rash risk:

  • Week 4–6: Lamotrigine 25 mg once daily
  • Week 6–8: 50 mg once daily
  • Week 8–10: 100 mg once daily (or 50 mg twice a day)
  • Week 10–12: Target dose 100 mg twice a day— the minimum dose recommended for future VSS trials, as 50 mg twice a day may be subtherapeutic.[1]

If tolerated and response is partial, consider titrating to 150 mg BID (maximum 200 mg twice a day).

Key safety considerations:

  • Separate magnesium dosing from lamotrigine by ≥2 hours to avoid theoretical chelation-related absorption reduction.
  • Avoid ginseng — probable UGT2B7 inhibition can elevate lamotrigine levels, with a documented case of DRESS syndrome.[11]
  • Monitor for rash at every visit during titration. Any rash warrants immediate discontinuation and evaluation.
  • Lamotrigine itself carries a risk of worsening VS symptoms in some patients. If symptoms worsen, taper and discontinue.[3]

First formal reassessment at Week 16 (12 weeks on nutraceuticals, ~6 weeks at target lamotrigine dose). Use a standardized symptom diary — the 30-day VSS diary validated by Puledda et al. is a useful tool for tracking symptom progression.[2]

—

PHASE 3 (Weeks 8–20, concurrent with Phase 2):

Behavioral and Rehabilitative Therapies

These modalities can be initiated during Phase 2 and run in parallel with pharmacotherapy titration.

   MBCT-Vision (if available)

  • 8-week group-based program, ideally starting around Week 8 when the patient has adjusted to the nutraceutical regimen and is mid-titration on lamotrigine.
  • The open-label study demonstrated symptom severity dropping from 7 to 4 (p<0.001) and impact on daily life from 6 to 2 (p<0.001), with continued improvement between Week 9 and Week 20 — suggesting ongoing neuroplastic benefit after the program ends.[12]
  • If formal MBCT-vision is unavailable, standard mindfulness-based stress reduction (MBSR) or individual CBT with a focus on attentional retraining and non-reactive awareness of visual symptoms is a reasonable alternative.[7][1]

   Neuro-Optometric Visual Rehabilitation Therapy (NORT)

  • Refer to a neuro-optometrist for oculomotor assessment. Approximately 40–50% of VSS patients have concurrent accommodative and vergence deficits that compound functional visual impairment.[10]
  • The Tsang et al. pilot study showed significant QOL improvement (NEI-VFQ-25 composite 68→77, p=0.0002) at 12 weeks of NORT.[13]
  • NORT and MBCT-vision can run concurrently — they target different aspects (oculomotor function vs. attentional/cognitive processing).

PHASE 4 (Week 16+):

Reassessment, Optimization, and Advanced Options

At the 16-week mark, perform a comprehensive reassessment:

Response Assessment

  • Compare baseline and current symptom severity using the VSS diary.
  • Categorize response: (a) meaningful improvement → continue current regimen; (b) partial improvement → optimize doses and add remaining modalities; (c) no improvement → consider modifications below.

If Partial or No Response — Optimization Strategies

  • Increase lamotrigine to 150–200 mg BID if tolerated and response is suboptimal at 100 mg BID.
  • Add anti-inflammatory dietary supplements discussed earlier in this conversation (omega-3 fatty acids, curcumin/turmeric, alpha-lipoic acid) to augment the anti-neuroinflammatory component.
  • Consider low-dose benzodiazepine (e.g., clonazepam 0.25–0.5 mg) for acute symptom exacerbations — benzodiazepines had the highest improvement rate (71.4%) in the systematic review, though long-term use carries dependency risk and this should be reserved for intermittent/rescue use.[9]

Advanced/Investigational Options

  • rTMS — If available in a research or clinical setting, low-frequency (1 Hz) inhibitory rTMS targeting the superior parietal lobule may be considered, based on the case report showing subjective improvement and objective EEG/fMRI changes. An open-label pilot trial (NCT04925232) is ongoing.[14][15]
  • Comorbidity-targeted treatment — Aggressively treat comorbid migraine (the nutraceutical regimen already serves dual purpose), depression/anxiety (noting that SSRIs may worsen VS — consider lamotrigine’s own mood-stabilizing properties, or bupropion as an alternative antidepressant less likely to worsen visual symptoms), and tinnitus (CBT for tinnitus has established efficacy and may generalize to VS).[1]

Protocol Summary Timeline

Phase

Timeframe

Interventions

Key Milestones

References

1: Foundation

Weeks 0–4

Education; environmental modifications; Mg 400–600 mg + B2 400 mg + CoQ10 300 mg; FL-41 lenses

Establish tolerability; eliminate exacerbating factors

[1], [2]

2: Pharmacotherapy

Weeks 4–16

Lamotrigine titration: 25 mg → 50 mg → 100 mg → 100 mg BID

Target dose by ~Week 10; first formal reassessment Week 16

[3]

3: Behavioral/Rehab

Weeks 8–20

MBCT-vision (8-week program) and/or NORT (12-week program)

Concurrent with Phase 2; continued benefit post-program

[4], [5]

4: Optimization

Week 16+

Reassess; optimize doses; add anti-inflammatory supplements; consider rTMS or benzodiazepine rescue

Ongoing management; repeat reassessment every 3 months

[6], [7], [8]

Critical Caveats

This protocol is necessarily expert-opinion level, as no RCTs exist for any VSS treatment and no published guidelines address comprehensive VSS management.[4][5] The phased approach is designed to maximize the chance of cumulative benefit while maintaining clear attribution of effects and adverse events. Each component has at least some evidence supporting its use, but the combination has never been formally studied. Patients should understand that VSS is typically a chronic, non-progressive condition, and that the goal is functional improvement and reduced distress rather than complete symptom elimination.[5]

References

  1. Treatment Effects and Comorbid Diseases in 58 Patients With Visual Snow. van Dongen RM, Waaijer LC, Onderwater GLJ, Ferrari MD, Terwindt GM. Neurology. 2019;93(4):e398-e403. doi:10.1212/WNL.0000000000007825.
  2. Evaluation of Treatment Response and Symptom Progression in 400 Patients With Visual Snow Syndrome. Puledda F, Vandenbussche N, Moreno-Ajona D, et al. The British Journal of Ophthalmology. 2022;106(9):1318-1324. doi:10.1136/bjophthalmol-2020-318653.
  3. Visual Snow: A Review on Pathophysiology and Treatment. Rusztyn P, Stańska W, Torbus A, Maciejewicz P. Journal of Clinical Medicine. 2023;12(12):3868. doi:10.3390/jcm12123868.
  4. Visual Snow Syndrome: Recent Advances in Understanding the Pathophysiology and Potential Treatment Approaches. Aeschlimann SA, Klein A, Schankin CJ. Current Opinion in Neurology. 2024;37(3):283-288. doi:10.1097/WCO.0000000000001258.
  5. Visual Snow: Updates and Narrative Review. Stern JI, Robertson CE. Current Pain and Headache Reports. 2024;28(2):55-63. doi:10.1007/s11916-023-01186-3.
  6. Visual Snow Syndrome: Therapeutic Implications. Ciuffreda KJ, Rutner D. Journal of Clinical Medicine. 2025;14(17):6070. doi:10.3390/jcm14176070.
  7. Mindfulness and MBCT-vision (Mindfulness-Based Cognitive Therapy Modified for Visual Symptoms) for Visual Snow Syndrome: A Therapeutic Perspective. Wong SH, Wingrove J. Frontiers in Neurology. 2025;16:1596642. doi:10.3389/fneur.2025.1596642.
  8. Effectiveness of High-Dose Riboflavin in Migraine Prophylaxis. A Randomized Controlled Trial. Schoenen J, Jacquy J, Lenaerts M. Neurology. 1998;50(2):466-70. doi:10.1212/wnl.50.2.466.
  9. Diagnostic and Management Strategies of Visual Snow Syndrome: Current Perspectives. Ayesha A, Riehle C, Leishangthem L. Eye and Brain. 2025;17:1-11. doi:10.2147/EB.S418923.
  10. Historical, Diagnostic, and Chromatic Treatment in Visual Snow Syndrome: A Retrospective Analysis. Han MHE, Ciuffreda KJ, Rutner D. Optometry and Vision Science : Official Publication of the American Academy of Optometry. 2023;100(5):328-333. doi:10.1097/OPX.0000000000002019.
  11. Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome Probably Induced by a Lamotrigine-Ginseng Drug Interaction. Myers AP, Watson TA, Strock SB. Pharmacotherapy. 2015;35(3):e9-e12. doi:10.1002/phar.1550.
  12. Visual Snow Syndrome Improves With Modulation of Resting-State Functional MRI Connectivity After Mindfulness-Based Cognitive Therapy: An Open-Label Feasibility Study. Wong SH, Pontillo G, Kanber B, et al. Journal of Neuro-Ophthalmology : The Official Journal of the North American Neuro-Ophthalmology Society. 2024;44(1):112-118. doi:10.1097/WNO.0000000000002013.
  13. The Efficacy of Neuro-Optometric Visual Rehabilitation Therapy in Patients With Visual Snow Syndrome. Tsang T, Shidlofsky C, Mora V. Frontiers in Neurology. 2022;13:999336. doi:10.3389/fneur.2022.999336.
  14. Repetitive Transcranial Magnetic Stimulation for Visual Snow Syndrome: Symptoms Relief and Changes in Brain Dynamics. A Case Report. Neri F, De Monte D, Benelli A, et al. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2026;47(5):416. doi:10.1007/s10072-026-09013-4.
  15. A Study Protocol for an Open-Label Feasibility Treatment Trial of Visual Snow Syndrome With Transcranial Magnetic Stimulation. Grande M, Lattanzio L, Buard I, et al. Frontiers in Neurology. 2021;12:724081. doi:10.3389/fneur.2021.724081.

Emphasis on Education

 

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

 

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

 

Should you wish more information regarding any of the subjects listed – or not listed –  here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

 

For more information, please contact Accurate Clinic.

 

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.

 

 

.